首頁 > 市場調查報告書 > 製藥

藥物開發開發業務受託機關

市場調查報告書

商品編碼

1524313

體內CRO 市場- 按動物模型（基於囓齒動物、非囓齒動物）、服務（生物分析和DMPK 研究、毒性研究）、藥物類型（小分子、大分子）、治療領域（腫瘤學、心臟病學）、結束-使用，全球預測（2024 - 2032）

In Vivo CRO Market - By Animal Model (Rodent-based, Non-rodent-based), Service (Bioanalysis & DMPK Studies, Toxicity Studies), Drug Type (Small Molecule, Large Molecule), Therapeutic Area (Oncology, Cardiology), End-use, Global Forecast (2024 - 2032)

出版日期: 2024年04月11日 | 出版商:

Global Market Insights Inc. | 英文 272 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在對先進臨床前測試和研究服務的需求不斷成長的推動下，體內 CRO 市場規模預計在 2024 年至 2032 年期間複合年成長率為 7.8%。隨著製藥和生物技術公司努力加快藥物開發時間並降低成本，他們擴大將體內研究外包給專業的 CRO。例如，2023 年 3 月，作為 NVIDIA AI 基金會的一部分，新的 BioNeMo 雲端服務加速了生命科學研究、藥物發現和蛋白質工程。這些組織提供進行複雜動物研究的專業知識，同時確保遵守監管標準並提供高品質的資料。

隨著 CRISPR 和先進影像技術等新技術的出現，體內研究變得更加複雜，能夠更深入地了解疾病機制和治療效果。這導致人們越來越依賴擁有必要基礎設施和專業知識來進行這些前沿研究的 CRO。精準醫學的不斷成長趨勢也推動了市場的成長，這需要廣泛的體內研究來開發標靶療法。

該行業分為動物模型、服務、藥物類型、治療領域、最終用途和地區。

根據服務，預計到 2032 年，毒性研究領域的體內 CRO 市場規模將大幅成長。 In vivo CRO 提供專業知識和先進設施來進行這些複雜的研究，同時遵守嚴格的監管指南並提供可靠的資料。

臨床藥理學領域的體內CRO 市場預計在2024 年至2032 年間將出現顯著的複合年成長率。對於確定其安全性、有效性和最佳效果至關重要給藥方案。專門從事臨床藥理學的體內 CRO 提供先進的能力來進行徹底、精確的研究，包括吸收、分佈、代謝和排泄 (ADME) 分析。

亞太地區體內 CRO 產業將在 2024 年至 2032 年期間實現令人印象深刻的成長，這歸因於製藥和生物技術產業的不斷擴大，以及研發活動的大量投資的推動。慢性病的盛行率不斷上升，加速了對新治療解決方案的需求，從而推動了對體內 CRO 服務的需求。先進基礎設施的存在和創新技術的採用將進一步推動區域市場的成長。

產業生態系統分析
產業影響力
- 成長動力
  - 製藥和生技公司增加外包
  - 藥品核准的嚴格監管環境
  - 專注於 CRO 的專業服務
  - 個人化醫療需求不斷成長
- 產業陷阱與挑戰
  - 智慧財產權問題
  - 動物模型使用的嚴格監管政策
成長潛力分析
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按動物模型，2021 - 2032

主要趨勢
基於囓齒動物
- 大鼠模型
- 小鼠模型
- 其他囓齒動物模型
不囓齒類動物

第 6 章：市場估計與預測：按服務分類，2021 - 2032 年

主要趨勢
生物分析和 DMPK 研究
毒性研究
- GLP毒理學研究
- 非 GLP 毒理學研究
其他服務

第 7 章：市場估計與預測：按藥物類型，2021 - 2032

主要趨勢
小分子藥物
大分子藥物
- 細胞與基因治療
- RNA療法
- 其他大分子藥物

第 8 章：市場估計與預測：按治療領域，2021 - 2032 年

主要趨勢
腫瘤學
臨床藥理學
心臟病學
傳染性疾病
神經病學
胃腸病學和肝病學
代謝與內分泌
眼科
自體免疫/發炎狀況
其他治療領域

第 9 章：市場估計與預測：依最終用途，2021 - 2032 年

主要趨勢
製藥及生物製藥公司
醫療器材企業
學術及研究機構

第 10 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 11 章：公司簡介

Biocytogen
Charles River Laboratories International Inc.
Crown Bioscience
Evotec
GemPharmatech
IQVIA Inc.
Icon Plc
Labcorp Drug Development
Parexel International Corporation
PsychoGenics Inc.
Taconic Biosciences, Inc.

簡介目錄

Product Code: 8993

In Vivo CRO Market size is estimated to register 7.8% CAGR between 2024-2032, driven by the increasing demand for advanced preclinical testing and research services. As pharmaceutical and biotechnology companies are striving to accelerate drug development timelines and reduce costs, they are increasingly outsourcing their in vivo studies to specialized CROs. For instance, in March 2023, as part of NVIDIA AI Foundations, the new BioNeMo Cloud Service accelerated life sciences research, drug discovery, and protein engineering. These organizations offer expertise in conducting complex animal studies while ensuring compliance with regulatory standards and providing high-quality data.

With the advent of new technologies, such as CRISPR and advanced imaging techniques, in vivo studies have become more sophisticated and capable of providing deeper insights into disease mechanisms and treatment effects. This has led to an increased reliance on CROs that possess the necessary infrastructure and expertise to conduct these cutting-edge studies. The growing trend of precision medicine, which requires extensive in vivo research to develop targeted therapies, is also boosting the market growth.

The industry is classified into animal model, service, drug type, therapeutic area, end use, and region.

Based on service, the in vivo CRO market size from the toxicity studies segment is anticipated to witness substantial growth through 2032. Regulatory authorities require comprehensive toxicity data before approving any new pharmaceutical products, making toxicity studies an essential part of the drug development process. In vivo CROs offer specialized expertise and advanced facilities to conduct these complex studies while adhering to stringent regulatory guidelines and providing reliable data.

In vivo CRO market from the clinical pharmacology segment is anticipated to observe a significant CAGR between 2024 - 2032. This is due to its cruciality in understanding the pharmacokinetics and pharmacodynamics of new drug candidates, which are crucial for determining their safety, efficacy, and optimal dosing regimens. In vivo CROs specializing in clinical pharmacology offer advanced capabilities to conduct thorough and precise studies, including absorption, distribution, metabolism, and excretion (ADME) analysis.

Asia Pacific in vivo CRO industry will record impressive growth over 2024-2032 attributed to the expanding pharmaceutical and biotechnology sectors, bolstered by significant investments in R&D activities. The increasing prevalence of chronic diseases is accelerating the need for new therapeutic solutions, thereby driving the demand for in vivo CRO services. The presence of advanced infrastructure and the adoption of innovative technologies will further boost the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing outsourcing by pharmaceutical and biotechnology companies
  - 3.2.1.2 Stringent regulatory landscape for drug approvals
  - 3.2.1.3 Focus on specialized services by CRO's
  - 3.2.1.4 Rising demand for personalized medicine
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Intellectual property rights issues
  - 3.2.2.2 Stringent regulatory policies for animal model use
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Model, 2021 - 2032 ($ Million)

5.1 Key trends
5.2 Rodent-based
- 5.2.1 Rat models
- 5.2.2 Mice models
- 5.2.3 Other rodent models
5.3 Non-rodent-based

Chapter 6 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Million)

6.1 Key trends
6.2 Bioanalysis & DMPK studies
6.3 Toxicity studies
- 6.3.1 GLP toxicology studies
- 6.3.2 Non-GLP toxicology studies
6.4 Other services

Chapter 7 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Million)

7.1 Key trends
7.2 Small-molecule drugs
7.3 Large-molecule drugs
- 7.3.1 Cell & gene therapy
- 7.3.2 RNA therapy
- 7.3.3 Other large molecule drugs

Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Million)

8.1 Key trends
8.2 Oncology
8.3 Clinical pharmacology
8.4 Cardiology
8.5 Infectious diseases
8.6 Neurology
8.7 Gastroenterology & hepatology
8.8 Metabolic & endocrine
8.9 Ophthalmology
8.10 Autoimmune / inflammatory conditions
8.11 Other therapeutic areas

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Million)

9.1 Key trends
9.2 Pharmaceutical & bio pharmaceutical companies
9.3 Medical device companies
9.4 Academic & research institutes

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa